On May 27, 2026, the U.S. Food and Drug Administration (FDA) approved pivekimab sunirine-pvzy (Decnupaz™), AbbVie’s CD123-directed antibody-drug conjugate (ADC), for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is an ultra-rare and aggressive hematologic malignancy with estimated U.S. incidence of only tens to about 100 new cases annually, leaving very limited treatment options. The drug received both Breakthrough Therapy Designation and Orphan Drug Designation, and was uniquely approved for both treatment-naïve and relapsed/refractory BPDCN. This article summarizes the pivotal CADENZA trial design, key efficacy, safety profile, and regulatory and clinical significance.
Patient Population
- Adult patients with BPDCN (blastic plasmacytoid dendritic cell neoplasm)
- Approval spans both treatment-naïve BPDCN and relapsed/refractory (R/R) BPDCN
- BPDCN is a rare hematologic malignancy with high CD123 (IL-3Rα) expression, characterized by skin lesions, lymphadenopathy, bone marrow infiltration, and frequent purpuric skin lesions at diagnosis
- Until now, the only FDA-approved BPDCN therapy was tagraxofusp-erzs (Elzonris, Stemline/Menarini), leaving an urgent need for post–CD123-targeted therapy options
Pivotal Trial Overview
The approval is based on data from the Phase 1/2 CADENZA trial, a multicenter, open-label, single-arm study evaluating two cohorts: treatment-naïve BPDCN (n = 33) and relapsed/refractory BPDCN (n = 51). Given BPDCN’s rarity, where large randomized controlled trials are impractical, CADENZA represents a pragmatic and meaningful trial design for the disease area.
| Item | CADENZA Trial |
|---|---|
| Design | Multicenter, open-label, single-arm, Phase 1/2 |
| Cohort 1 (TN) | n = 33, treatment-naïve BPDCN |
| Cohort 2 (R/R) | n = 51, relapsed/refractory BPDCN |
| Dose | pivekimab sunirine 0.045 mg/kg IV every 3 weeks |
| Primary endpoint | Complete response rate (CR + CR with skin residual / CRc) |
| Key secondary endpoints | Duration of response (DoR), OS, PFS, safety |
Pivekimab sunirine-pvzy is composed of a humanized monoclonal antibody targeting CD123 covalently linked to DGN549, an indolinobenzodiazepine pseudodimer (IGN) DNA alkylating payload. CD123 (IL-3 receptor α chain, IL-3Rα) is nearly universally overexpressed on BPDCN tumor cells while having low expression on normal hematopoietic stem cells, making it an excellent selective target. After internalization into CD123-positive cells and lysosomal cleavage of the linker, DGN549—which forms DNA interstrand crosslinks—is released, inducing tumor cell apoptosis.
For BPDCN, no new FDA approval had occurred since tagraxofusp-erzs (a CD123-targeted immunotoxin fusion protein) was approved in 2018—a roughly 8-year gap. For patients in the R/R setting after tagraxofusp, or those unable to use tagraxofusp due to its capillary leak syndrome (CLS) toxicity, this drug provides a new treatment option with a different mechanism of action.
Key Efficacy Results
| Endpoint | TN BPDCN (n=33) | R/R BPDCN (n=51) |
|---|---|---|
| CR + CRc rate | 69.7% | 15.7% |
| Median DoR of CR/CRc | 9.7 months | 9.2 months |
| Median follow-up | 21.5 months | 24.1 months |
In the treatment-naïve BPDCN cohort, pivekimab sunirine-pvzy monotherapy delivered a CR + CRc rate of 69.7%—meaning about 7 out of every 10 patients achieved complete response (or CRc with residual skin disease only). This is an extraordinarily high single-agent CR rate for an ultra-rare disease. Median DoR of 9.7 months is practically meaningful for bridge-to-transplant strategies. Since allogeneic hematopoietic stem cell transplant (allo-HSCT) post–CR is key to long-term prognosis in BPDCN, a drug that delivers deep responses at high frequency holds important clinical positioning by making transplant strategies feasible.
In the R/R BPDCN cohort, the CR + CRc rate was 15.7%—about 1 in 6 R/R patients achieving CR. R/R BPDCN carries an extremely poor prognosis; conventional salvage chemotherapy yields median OS in the range of just months. In this context, a 15.7% CR rate represents clinically meaningful salvage efficacy. The median DoR of 9.2 months in R/R—comparable to the TN cohort—suggests responders achieve sustained disease control.
That these effects were demonstrated with long follow-up (median 21.5–24.1 months) provided high credibility for single-arm rare disease data and supported FDA’s full approval decision.
Safety Profile
Pivekimab sunirine-pvzy’s key adverse events center on the hematologic toxicities expected from a CD123 ADC and the IGN payload’s toxicity profile. A key differentiator from tagraxofusp-erzs is the markedly lower incidence of capillary leak syndrome (CLS).
- Myelosuppression—thrombocytopenia, neutropenia, anemia at high frequency. Grade ≥ 3 thrombocytopenia ~30%, neutropenia ~35%
- Infections—risk of bacterial/fungal infections against the backdrop of neutropenia. Febrile neutropenia management is critical
- Infusion reactions—manageable with pre-medication (antihistamines, steroids)
- Hepatic function abnormalities—AST/ALT elevation observed
- Capillary leak syndrome (CLS)—lower frequency and severity vs. tagraxofusp (key differentiator)
| Adverse Event | All Grades | Grade ≥3 |
|---|---|---|
| Thrombocytopenia | ~50% | ~30% |
| Neutropenia | ~50% | ~35% |
| Anemia | ~45% | ~20% |
| Fatigue | ~40% | ~5% |
| Infusion reactions | ~30% | ~3% |
| AST/ALT elevation | ~25% | ~7% |
The main fatal adverse event risk identified is neutropenia-related infection, making appropriate infection management infrastructure (G-CSF use, prophylactic antimicrobials, regular blood count monitoring) a prerequisite for clinical adoption.
Regulatory Significance and Clinical Positioning
The significance of this approval can be summarized along three axes.
(1) Establishment of a second pillar in BPDCN treatment. Since the 2018 approval of tagraxofusp-erzs (Elzonris), BPDCN had seen no new approved therapies for about 8 years. Tagraxofusp targets CD123 via a diphtheria toxin fusion protein modality, with CLS as a notable clinical challenge. Pivekimab sunirine-pvzy targets the same CD123 but via an ADC modality, substantially reducing CLS risk—providing a second treatment option for post-tagraxofusp R/R settings and patients at high CLS risk.
(2) Positioning as bridge-to-transplant therapy. In BPDCN, allogeneic HSCT post-CR is key to long-term prognosis. The CR + CRc rate of 69.7% and 9.7-month DoR in TN BPDCN enables deep disease control during transplant preparation. This positions the drug strategically to contribute to overall improvement in BPDCN treatment outcomes.
(3) Clinical establishment of the CD123 ADC platform. CD123 is expressed not only in BPDCN but also in acute myeloid leukemia (AML), CML blast phase, and myelodysplastic syndromes (MDS). The BPDCN approval of pivekimab sunirine-pvzy establishes the clinical viability of CD123 ADCs and strengthens the path for indication expansion into AML and other hematologic malignancies. AbbVie positions this drug at the core of its hematology ADC pipeline, with this approval further advancing the company’s hematology-oncology strategy.
My Thoughts and Future Outlook
The arrival of a second approved drug for BPDCN—an ultra-rare disease—is significant. Since tagraxofusp-erzs’s 2018 approval, BPDCN patients have effectively had a single option for 8 years. Patients unable to use it due to CLS, or those relapsing after tagraxofusp, now have a meaningful additional option. Same CD123 target, different modality (immunotoxin vs ADC)—and a markedly improved toxicity profile. FDA’s decision to grant full approval based on 84 patients in a Phase 1/2 study—for a disease with tens to ~100 annual new U.S. cases—reflects a pragmatic and realistic approach to rare disease drug development.
The 69.7% CR + CRc in treatment-naïve BPDCN is a strikingly practical bridge-to-transplant figure. Since allo-HSCT post-CR offers a chance at long-term survival in BPDCN, a drug that delivers deep responses at high frequency translates into more patients reaching potentially curative transplant. The 15.7% CR + CRc in R/R looks low at first glance, but given the brutal prognosis of R/R BPDCN (median OS measured in months on salvage chemotherapy), 1 in 6 achieving deep response is genuinely valuable salvage therapy. Establishing infection control and myelosuppression management infrastructure will determine real-world success.
Next-wave developments include: (1) head-to-head comparison or sequential treatment strategy optimization with tagraxofusp-erzs, (2) indication expansion into CD123-positive AML and MDS, (3) combination regimens with intensive chemotherapy or pre-allo-HSCT conditioning, (4) molecular subtype–level efficacy analysis in BPDCN. The establishment of a second treatment option in BPDCN—an ultra-rare disease—will be remembered as the starting point for the CD123 ADC platform’s broader hematology expansion.
Related Articles
- Oncology Drug Approval News Flash: FDA Approves Durvalumab (Imfinzi, AstraZeneca) + BCG for BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
- Oncology Drug Approval News Flash: FDA Approves Datopotamab Deruxtecan-dlnk (Datroway, Daiichi Sankyo/AstraZeneca) for 1L Unresectable or Metastatic TNBC (PD-(L)1 Ineligible)
- Oncology Drug Approval News Flash: FDA Approves Atezolizumab (Tecentriq, Genentech/Roche) for Adjuvant Treatment of Muscle-Invasive Bladder Cancer in Patients with Molecular Residual Disease
- Oncology Drug Approval News Flash: FDA Approves Zenocutuzumab-zbco (Bizengri, Merus N.V.) for Advanced, Unresectable or Metastatic Cholangiocarcinoma
- Oncology Drug Approval News Flash: FDA Approves Trastuzumab Deruxtecan (Enhertu, Daiichi Sankyo/AstraZeneca) for HER2-Positive Early Breast Cancer in Two Indications (Neoadjuvant and Adjuvant)
Comments